QIANJIANG YONGAN PHARM

Qianjiang Yongan Pharmaceutical trades flat at CN¥11.27, amid a quiet acquisition announcement, while its niche taurine business attracts long‑term investors.

Qianjiang Yongan Pharm’s steady 0% return hides solid fundamentals: a stable taurine focus, a 3.4 billion‑CNY cap, and a clear path to the 200‑day SMA—ideal for patient investors seeking defensive growth.